Claims for Patent: 9,211,205

Summary for Patent: 9,211,205

Title:	Bioabsorbable medical device with coating
Abstract:	A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a bioabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.
Inventor(s):	Cottone; Robert J. (Davie, FL)
Assignee:	ORBUSNEICH MEDICAL, INC. (Ft. Lauderdale, FL)
Application Number:	14/158,217
Patent Claims:	1. An expandable stent, comprising bioabsorbable polymer scaffold and a coating, wherein the expandable stent comprises a plurality of first meandering strut patterns forming an interconnected mesh, and at least one second strut pattern comprising a hoop circumferential about the longitudinal axis of the expandable stent, wherein the second strut pattern crystallizes when the stent is expanded, the bioabsorbable polymer scaffold comprising, at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co PEG moiety, linked with a modifying polymer comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-.epsilon.-caprolactone) or poly (D-lactide-co-.epsilon.-caprolactone), wherein the coating comprises a ligand specific to an progenitor endothelial cell surface antigen selected from the group consisting of CD34 CD45, CD133, CD14, CDw90, CD117, HLA-DR, VEGFR-1, VEGFR-2, CD146, CD130, CD131, stem cell antigen, stem cell factor 1, Tie-2, MCH-H-2Kk and MCH-HLA-DR. 2. The expandable stent of claim 1, wherein the second strut pattern further comprises a through-void. 3. The expandable stent of claim 1, wherein the ligand is configured to bind target cells in vivo. 4. The expandable stent of claim 1, wherein the coating further comprises a bioabsorbable matrix. 5. The expandable stent of claim 4, wherein the bioabsorbable matrix comprises at least one of the group consisting of: dextran, tropoelastin, elastin, laminin, fibronectin, fibrin, collagen, basement membrane proteins, and cross-linked tropoelastin. 6. The expandable stent of claim 1, further comprising a pharmacological substance. 7. The expandable stent of claim 6, wherein the pharmacological substance is at least one of the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, pimecrolimus, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17.beta.-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol. 8. The expandable stent of claim 6, wherein the stent is a drug-eluting stent.

Details for Patent 9,211,205

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2026-10-20
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2026-10-20